毛霉菌病是一种与高死亡率相关的严重和新出现的侵袭性真菌感染。早期诊断对于启动特定的抗真菌治疗至关重要。分子工具目前代表最有效的诊断方法。目前,标准化的内部实时PCR方法被广泛用于诊断毛霉菌病。我们的研究旨在评估两种商业实时PCR检测方法-真菌实时PCR试剂盒和MycoGENIE曲霉-Mucoralesspp之间的MucoralesDNA检测协议。实时PCR试剂盒-与内部PCR的比较。我们使用内部PCR回顾性分析了先前鉴定为Mucorales阳性的58个样品。这些样本,从22名已证实或可能的毛霉菌病患者中获得,用两种商业试剂盒进行了测试。此外,40例无毛霉菌病患者的样本作为阴性对照。我们的发现表明,MycoGENIE试剂盒在检测通过内部PCR鉴定为阳性的样品中的MucoralesDNA方面表现出卓越的性能。值得注意的是,我们观察到最小的变化在循环阈值(CT)值比较时,MycoGENIE试剂盒的结果与那些内部PCR,平均相差1.8个周期。相比之下,与内部PCR相比,真菌试剂盒在CT值方面表现出更大的差异,平均相差4.1个周期。MycoGENIE试剂盒与内部PCR表现出非常好的一致性(κ为0.82),用于检测各种样品类型的MucoralesDNA。这些发现对于选择可用于在临床微生物学实验室中诊断毛霉菌病的试剂盒非常重要。
目的:毛霉菌病的早期诊断对于有效治疗至关重要。通过PCR检测血清中的MucoralesDNA彻底改变了这种感染的诊断。然而,使用内部方法可能是耗时的。商业试剂盒的可用性消除了内部测定开发的需要,减少实验室工作量并确保在不同医疗保健环境中的一致性能。目前,有几种商业检测方法可用,但是许多人的评价有限。在这项研究中,我们比较了两种商业试剂盒,发现MycoGENIE试剂盒提供了一种有希望的替代内部方法。
Mucormycosis is a severe and emerging invasive fungal infection associated with high mortality rates. Early diagnosis is crucial for initiating specific antifungal treatment, with molecular tools currently representing the most efficient diagnostic approach. Presently, a standardized in-house real-time PCR method is widely employed for diagnosing mucormycosis. Our study aimed to evaluate the agreement for the
Mucorales DNA detection between two commercial real-time PCR assays-the Fungiplex
Mucorales Real-Time PCR Kit and the MycoGENIE Aspergillus-
Mucorales spp. Real-Time PCR Kit-in comparison with the in-house PCR. We retrospectively analyzed 58 samples previously identified as positive for
Mucorales using the in-house PCR. These samples, obtained from 22 patients with proven or probable mucormycosis, were tested with both commercial kits. Additionally, samples from 40 patients without mucormycosis served as negative controls. Our findings revealed that the MycoGENIE Kit demonstrated superior performance in detecting
Mucorales DNA in samples identified as positive by the in-house PCR. Notably, we observed minimal variability in cycle threshold (CT) values when comparing the results of the MycoGENIE Kit with those of the in-house PCR, with an average difference of 1.8 cycles. In contrast, the Fungiplex Kit exhibited a larger discrepancy in CT values compared to the in-house PCR, with an average difference of 4.1 cycles. The MycoGENIE Kit exhibited very good agreement (kappa of 0.82) with the in-house PCR for detecting Mucorales DNA across various sample types. These findings are important for the choice of kits that could be used to diagnose mucormycosis in clinical microbiology laboratories.
OBJECTIVE: Early diagnosis of mucormycosis is crucial for initiating effective treatment. The detection of
Mucorales DNA by PCR in serum has revolutionized the diagnosis of this infection. However, the use of in-house methods can be time consuming. The availability of a commercial kit eliminates the need for in-house assay development, reducing laboratory workload and ensuring consistent performance across different healthcare settings. Currently, there are several commercial assays available, but many have limited evaluation. In this study, we compared two commercial kits and found that the MycoGENIE Kit offers a promising alternative to the in-house method.